Source: Annual Congress 2002 - Drug resistance
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. J. Stefanovic, M. M. Danilovic, L. T. Tomic (Belgrade, Yugoslavia). Mycobacterium tuberculosis resistance. Eur Respir J 2002; 20: Suppl. 38, 2227

Member's Comments

No comment yet.

Related content which might interest you: Multi-drug-resistant tuberculosis Source: ERS Course 2018 - Summer school of paediatric respiratory medicine Year: 2018 Multi-drug-resistant tuberculosis Source: ERS Course 2019 - Summer school of paediatric respiratory medicine 2019 Year: 2019 Drug resistance of Mycobacterium tuberculosis isolated from tuberculosis inflammatory foci Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001 Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012 Mycobacterium tuberculosis drug resistance surveillance in Belarus Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 The spectrum of drug susceptibility of slow-growing nontuberculous mycobacteria (MAC, M. kansasii, M. xenopi) Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015 Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001 Discriminating active from latent tuberculosis by Mycobacterium tuberculosis (MTB)-peptide specific immunoresponses Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008 Resistance genotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Serbia Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017 Infection of the respiratory mucosa by Mycobacterium avium complex (MAC), Mycobacterium tuberculosis (MTB) and Mycobacterium smegmatis (MS) Source: Eur Respir J 2001; 18: Suppl. 33, 308s Year: 2001 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017 Circulation of multidrug resistant strains of Mycobacterium tuberculosis in Abkhasia Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006 Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017 Biological properties of Mycobacterium tuberculosis (Mtb) resistant to biocides Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis Source: Eur Respir J 2010; 35: 692-694 Year: 2010 Investigation of the inhibition of adherence of Mycobacterium avium complex (MAC) and Mycobacterium tuberculosis (MTB) to the respiratory mucosa Source: Eur Respir J 2001; 18: Suppl. 33, 480s Year: 2001